| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Robert N Schuck | |
| Michael Pacanowski | |||
| Elizabeth Marek | |||
| Hobart Rogers | |||
| P2860 | cites work | Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing | Q24632749 |
| Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632927 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| Individualized medicine from prewomb to tomb | Q29525070 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine | Q33336860 | ||
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus | Q33882066 | ||
| Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir | Q33956146 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans | Q34172669 | ||
| 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q34231154 | ||
| Severe adverse cutaneous reactions to drugs | Q34314152 | ||
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis | Q34624862 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Clinical pharmacology and pharmacogenetics of thiopurines | Q34782066 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Cytochrome p-450 polymorphisms and response to clopidogrel | Q34910228 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Genomics and drug response | Q35252277 | ||
| Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk | Q35594031 | ||
| Personalizing medicine with clinical pharmacogenetics | Q35791989 | ||
| Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing | Q36029478 | ||
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin | Q37196787 | ||
| A pharmacogenetic versus a clinical algorithm for warfarin dosing | Q37616712 | ||
| Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come | Q37721661 | ||
| Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer | Q37825721 | ||
| Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. | Q37908444 | ||
| HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review | Q38058271 | ||
| Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan | Q39268755 | ||
| Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine. | Q39822900 | ||
| Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study | Q43121603 | ||
| Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer | Q43292375 | ||
| Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions | Q45893637 | ||
| A randomized trial of genotype-guided dosing of warfarin. | Q51140132 | ||
| Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. | Q51859231 | ||
| Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. | Q52579212 | ||
| Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C | Q73257107 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1999-2006 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Clinical and regulatory considerations in pharmacogenetic testing | |
| P478 | volume | 73 |
Search more.